The C X C chemokine receptor 4 (CXCR4) belongs to G protein-coupled receptor (GPCR) family. GPCRs superfamily provides many desirable therapeutic targets in cancer and other diseases. At present, CXCR4 has been discovered strongly expressed in multiple types of cancers. In addition, CXCR4 is also involved in HIV virus infection. These biological functions supports that CXCR4 could be potentially an ideal target for tumors, hematopoietic stem cell mobilization, HIV and other diseases. (Enjoy the Read CXCR4 Article)

A few months early, BioLineRx Ltd had completed a successful pre-NDA meeting regarding a chemokine receptor CXCR4 antagonist (Motixafortide). In particular, the biopharmaceutical company further announced that Motixafortide NDA submission will be on track for H1 2022 (January to June). It is expected to be the second CXCR4 antagonist FDA approved for cancer therapy after Plerixafor. Apparently, CXCR4 provides a perspective on strategies that can lead to future drug discoveries for a variety of diseases, especially in tumors.

To fully serve pharmaceutical companies in their CXCR4 based drug research for tumors, hematopoietic stem cell mobilization, HIV, autoimmune diseases, etc., CUSABIO has launched CXCR4 active protein product (Code: CSB-MP006254HU(F1)) to help your research on CXCR4 mechanism or its potential clinical applications.

Recombinant Human C-X-C chemokine receptor type 4 (CXCR4)-VLPs (Active) In Stock High Specificity Validated by Western Blot (WB) Excellent Bioactivity Validated by Functional ELISA CSB-MP006254HU(F1) is detected by Mouse anti-6*His monoclonal antibody. Immobilized Human CXCR4 at 10 μg/ml can bind Anti-CXCR4 recombinant antibody (CSB-RA006254MA01HU), the EC50 is 101.7-253.6 ng/mL.

CUSABIO appreciates the critical role that you and our products play in research since many scientists are diligently pursuing their research to further scientific innovation and discovery. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.